Literature DB >> 9708798

Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples.

R Ward1, N Hawkins, R O'Grady, C Sheehan, T O'Connor, H Impey, N Roberts, C Fuery, A Todd.   

Abstract

The enriched polymerase chain reaction (PCR) assay has been used extensively in the detection of ras gene mutations in many types of human malignancies. Although it is very sensitive, it has a number of features that limit its use in the routine diagnostic laboratory. The aim of this study was to develop a novel enriched PCR strategy, in which the concurrent activity of the restriction enzyme BstNI and Taq polymerase allowed the amplification of mutant K-ras while inhibiting the formation of wild-type product. This restriction endonuclease-mediated selective PCR assay uses three sets of primers, together with BstNI, in the reaction mix, and the amplification products are analyzed by gel electrophoresis. The reliability of the restriction endonuclease-mediated selective PCR assay to detect activated K-ras was determined in a variety of clinical samples, including 139 fresh colorectal carcinomas and 113 paraffin-embedded blocks from 80 separate tumors of the colon and rectum, pancreas, breast, or kidney. Codon 12 mutations of the K-ras oncogene were identified in DNA from both fresh and paraffin-embedded tumors in a rapid, sensitive, and reproducible manner. Mutations were detected in 33 (24%) of the fresh colorectal cancers and 16 (20%) of the paraffin-embedded tumors. These results were 97% concordant in cases in which paraffin blocks and fresh specimens from the same tumor were available for analysis. We conclude that restriction endonuclease-mediated selective PCR is a sensitive, rapid, and robust assay for the detection of point mutations in a variety of clinical samples. Importantly, there is no need for manipulation of the sample once the PCR has been set up, and therefore, the chance of contamination is significantly reduced. In contrast to previous assays, restriction endonuclease-mediated selective PCR is not labor intensive, and its format is suitable for use in routine diagnostic laboratory.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708798      PMCID: PMC1852993          DOI: 10.1016/S0002-9440(10)65581-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology.

Authors:  D Shibata; W J Martin; N Arnheim
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

2.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue.

Authors:  S E Goelz; S R Hamilton; B Vogelstein
Journal:  Biochem Biophys Res Commun       Date:  1985-07-16       Impact factor: 3.575

3.  Mutational activation of k-ras oncogene in human breast-tumors.

Authors:  M Koffa; V Malamoumitsi; N Agnantis; D Spandidos
Journal:  Int J Oncol       Date:  1994-03       Impact factor: 5.650

4.  The effect of formalin fixation on restriction endonuclease digestion of DNA and PCR amplification.

Authors:  S Hamazaki; M Koshiba; T Habuchi; R Takahashi; T Sugiyama
Journal:  Pathol Res Pract       Date:  1993-06       Impact factor: 3.250

5.  K-ras mutation and loss of heterozygosity of chromosome 17p and survival in colorectal cancer.

Authors:  C Fung; T Bragg; R Newland; O Dent; G Nicholson; L Bokey; P Chapuis
Journal:  Aust N Z J Surg       Date:  1997-05

6.  A rapid PCR ELISA for the detection of activated K-ras in colorectal cancer.

Authors:  R L Ward; F Santiago; N J Hawkins; D Coomber; T O'connor; A V Todd
Journal:  Clin Mol Pathol       Date:  1995-10

7.  Stability of K-ras mutations throughout the natural history of human colorectal cancer.

Authors:  L Losi; J Benhattar; J Costa
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces.

Authors:  C Ratto; G Flamini; L Sofo; P Nucera; M Ippoliti; G Curigliano; G Ferretti; A Sgambato; M Merico; G B Doglietto; A Cittadini; F Crucitti
Journal:  Dis Colon Rectum       Date:  1996-11       Impact factor: 4.585

9.  Genetic diagnosis of lymph-node metastasis in colorectal cancer.

Authors:  N Hayashi; I Ito; A Yanagisawa; Y Kato; S Nakamori; S Imaoka; H Watanabe; M Ogawa; Y Nakamura
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

10.  Point mutations of c-ras genes in human bladder cancer and kidney cancer.

Authors:  Y Nagata; M Abe; K Kobayashi; S Saiki; T Kotake; K Yoshikawa; R Ueda; E Nakayama; H Shiku
Journal:  Jpn J Cancer Res       Date:  1990-01
View more
  26 in total

1.  Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.

Authors:  R Ward; A Meagher; I Tomlinson; T O'Connor; M Norrie; R Wu; N Hawkins
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Mutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs.

Authors:  Seung-Tae Lee; Ji-Youn Kim; Min-Jung Kown; Sun Wook Kim; Jae Hoon Chung; Myung-Ju Ahn; Young Lyun Oh; Jong-Won Kim; Chang-Seok Ki
Journal:  J Mol Diagn       Date:  2011-09-14       Impact factor: 5.568

3.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Authors:  Wilko Weichert; Christiane Schewe; Annika Lehmann; Christine Sers; Carsten Denkert; Jan Budczies; Albrecht Stenzinger; Hans Joos; Olfert Landt; Volker Heiser; Christoph Röcken; Manfred Dietel
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

4.  Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells.

Authors:  Hiroaki Shimoyamada; Takuya Yazawa; Hanako Sato; Koji Okudela; Jun Ishii; Masashi Sakaeda; Korehito Kashiwagi; Takehisa Suzuki; Hideaki Mitsui; Tetsukan Woo; Michihiko Tajiri; Takahiro Ohmori; Takashi Ogura; Munetaka Masuda; Hisashi Oshiro; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

5.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Liying Yan; Mami Cantor; Chungdak Namgyal; Mari Mino-Kenudson; Gregory Y Lauwers; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

6.  Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma.

Authors:  John A Tynan; Payam Mahboubi; Lesley L Cagasan; Dirk van den Boom; Mathias Ehrich; Paul Oeth
Journal:  J Mol Diagn       Date:  2011-05-06       Impact factor: 5.568

7.  Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.

Authors:  Koji Okudela; Takuya Yazawa; Tetsukan Woo; Masashi Sakaeda; Jun Ishii; Hideaki Mitsui; Hiroaki Shimoyamada; Hanako Sato; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Takashi Takahashi; Haruhiko Sugimura; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

8.  Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis.

Authors:  Koji Okudela; Takuya Yazawa; Jun Ishii; Tetsukan Woo; Hideaki Mitsui; Tomoyasu Bunai; Masashi Sakaeda; Hiroaki Shimoyamada; Hanako Sato; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Haruhiko Sugimura; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 9.  PCR-based methods for the enrichment of minority alleles and mutations.

Authors:  Coren A Milbury; Jin Li; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2009-02-06       Impact factor: 8.327

10.  CpG island methylation is a common finding in colorectal cancer cell lines.

Authors:  C M Suter; M Norrie; S L Ku; K F Cheong; I Tomlinson; R L Ward
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.